keyhole limpet hemocyanin + bevacizumab

**Keyhole limpet hemocyanin + bevacizumab** is a combination of two biologic agents, each with different mechanisms of action, used experimentally as a cancer immunotherapy. **Keyhole limpet hemocyanin (KLH)** is a large, highly immunogenic glycoprotein derived from the marine mollusk _Megathura crenulata_; it is potently immunostimulatory and functions as a vaccine carrier protein or direct immune stimulant in cancer contexts[1][5][9]. **Bevacizumab** is a humanized monoclonal antibody that targets vascular endothelial growth factor A (VEGF-A), inhibiting angiogenesis to starve tumors of blood supply[2][6]. While each is approved or studied independently, their combination is being explored for synergistic enhancement of anti-tumor immune activity—KLH to boost general or antigen-specific immune responses and bevacizumab to suppress tumor angiogenesis and modulate the immune microenvironment[6]. There is no established brand name or wide regulatory approval for this combination; its use is investigational.

Other names

KLH + bevacizumab